innoVitro - Statement about FLEXcyte technology

  “We have been working with Nanion for several years on technology development projects and joint commercialization. Nanion is a prime example of an agile approach and customer orientation.”

Dr. Matthias Gossmann
co-founder and CEO at innoVitro, Germany. (CRO, FLEXcyte Service Provider)

  “Human iPSC-derived cardiomyocytes are the future of safe and efficient drug development. The FLEXcyte technology provides a tool for functional cardiac toxicology and efficacy screening on these cells. Force-frequency relation are the subject of current scientific discussions and require an assay technology that can accurately quantify them and we meet this need with the FLEXcyte 96.”

Dr. Peter Linder
CTO innoVitro, Germany. (CRO, FLEXcyte Service Provider)